TKI response rate
Research type
Research Study
Full title
A retrospective analysis of tyrosine kinase inhibitor (TKI) efficacy and BCR-ABL mutation status in patients with CML
IRAS ID
173844
Contact name
Dragana Milojkovic
Contact email
Sponsor organisation
ARIAD Pharmaceuticals, Inc
Duration of Study in the UK
0 years, 5 months, 31 days
Research summary
This project involves the collection of limited and specific medical data from patients suffering from chronic myeloid leukemia (CML) and in particular their levels of response to the various anticancer drugs they have taken. It is well known that the presence of mutations in the CML causing gene confers different levels of resistance to the drugs currently available to treat CML. We aim to gather data on the response rates to these different drugs and then categorize the data according to the specific mutation the patient has. We aim to collate response rates from at least 15 patients per mutant, and for as many mutants as possible.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
15/NW/0861
Date of REC Opinion
27 Oct 2015
REC opinion
Favourable Opinion